RÉSUMÉ
Objective Based on the concept of quality marker (Q-marker), a chemical method was developed to evaluate the quality of the multi-original medicinal material “Meiduoluomi” and predict its Q-marker. Methods Firstly, the Q-marker were preliminary predicted based on the relationship between genetic relationship and biosynthesis pathway, pharmacological activity and chemical composition. Secondly, the main active components were determined by UHPLC. The analysis was performed using ACQUITY UHPLC HSS C18 column (100 mm × 2.1 mm, 1.8 μm); Mobile phase was acetonitrile (A)-0.3% acetic acid water (B) with gradient elution; The flow rate was 0.2 mL/min; The column temperature was 35 ℃; The detection wavelength was 320 nm. Results A new method for simultaneous determining five compounds of meiduoluomi was established, including chlorogenic acid, caffeic acid, 3,4-dicaffeoylquinic acid, 3,5-dicaffeoylquinic acid, and 4,5-dicaffeoylquinic acid. The linear relationship of them was good at the range of 9.60-480.00, 10.27-513.50, 10.08-504.03, 9.64-482.80, and 3.82-380.24 mg/L, respectively; And the average recovery rates were 102.43%, 99.78%, 99.39%, 103.12%, and 101.83%, respectively. The five components were detected in each sample and the total content of the five components was more than 10% in the herbal medicine. It was suggested that the five components can be used as a Q-marker of meiduoluomi for quality control. Conclusion The coffeic acid components are scientific and reasonable to be considered as a Q-marker of meiduoluomi. The developed UHPLC method can be used for the quality control of meiduoluomi. This study provides new idea for the rational evaluation of multi-original medicinal material based on Q-marker.
RÉSUMÉ
Objective: To study the antidiabetic constituents of Tibetan Medicine "Meiduoluomi". Methods: Erigeron multiradiatus (EM) is one of the crude materials. The chemical constituents in EM were extracted and isolated by extraction and macroporous resin column. The inhibitory activities of the extracts against aldose reductase (AR) were evaluated in vitro to make sure the active fragments. Diabetic rats induced by streptozotocin were randomly divided into four groups: model (distilled water), positive control (epalrestat 10 mg/kg), EM II low-and high-dosage (200, 400 mg/kg) groups. The rats were ig administered once daily for 11 weeks. The rat normal sign, body weight, urine glucose, blood glucose, hemodynamics, and cardiac function parameters were determined. Results: Both EM I and EM II showed the inhibitory activities against AR with IC50 values of 0.64 and 0.12 mg/mL, respectively. Compared with diabetic group, body weight, heart rate, left ventricular end diastolic pressure average (LEVDP) and the left ventricular maximum rate of pressure development (+dp/dtmax) in EM II group were significantly improved, while blood glucose was decreased (P < 0.05, 0.01, 0.001). Conclusion: EM II demonstrates the obvious inhibitory activity on AR, and could improve the hemodynamics and protect heart function, which may be the antidiabetic active constituents of "Meiduoluomi".